Department of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
Auto-generated profile, based on publicly available information
Hui Zeng
Department of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
Tumor-initiating cells (TICs) reprogram their metabolic features to meet their bioenergetic, biosynthetic, and redox demands. Our previous study established a role for wild-type isocitrate dehydrogenase 1 (IDH1 WT ) as a potential diagnostic and prognostic biomarker for non–small cell lung cancer (NSCLC), but how IDH1 WT modulates NSCLC progression remains elusive. Here, we report that IDH1 WT activates serine biosynthesis by enhancing the expression of phosphoglycerate dehydrogenase (PHGDH) and phosphoserine aminotransferase 1 (PSAT1), the first and second enzymes of de novo serine synthetic pathway. Augmented serine synthesis leads to GSH/ROS imbalance and supports pyrimidine biosynthesis, maintaining tumor initiation capacity and enhancing gemcitabine chemoresistance. Mechanistically, we identify that IDH1 WT interacts with and stabilizes PHGDH and fragile X–related protein-1 (FXR1) by impeding their association with the E3 ubiquitin ligase parkin by coimmunoprecipitation assay and proximity ligation assay. Subsequently, stabilized FXR1 supports PSAT1 mRNA stability and translation, as determined by actinomycin D chase experiment and in vitro translation assay. Disrupting IDH1 WT -PHGDH and IDH1 WT -FXR1 interactions synergistically reduces NSCLC stemness and sensitizes NSCLC cells to gemcitabine and serine/glycine–depleted diet therapy in lung cancer xenograft models. Collectively, our findings offer insights into the role of IDH1 WT in serine metabolism, highlighting IDH1 WT as a potential therapeutic target for eradicating TICs and overcoming gemcitabine chemoresistance in NSCLC.
Background: This study aimed to establish a nomogram for predicting risk of recurrence and provide a model for decision-making between lobectomy and sublobar resection in patients with stage IA lung adenocarcinoma.Methods: Patients diagnosed with stage IA lung adenocarcinoma (LUAD) between December 2010 and October 2018 from Cancer Hospital Chinese Academy of Medical Sciences were included. Patients were randomly assigned to training and validation cohorts, accounting for 70% and 30% of the total cases, respectively. We collected laboratory variables before surgery. Univariate and multivariate analyses were performed in the training cohort to identify variables significantly associated with recurrence-free survival (RFS) which were subsequently used to construct a nomogram. Validation was conducted in both cohorts. A receiver operating characteristic curve was used to determine the optional cutoff values of the scores calculated from the nomogram. Patients were then divided into low- and high-risk groups. Survival was performed to determine if the nomogram could guide the operation method.Results: A total of 543 patients were included in this study. Gender, albumin level, carcinoembryonic antigen level and cytokeratin-19-fragment level were included in the nomogram. In both cohorts, the nomogram stratified the patients into high- and low-risk groups in terms of RFS. In particular, there was a significant difference in RFS between lobectomy and sublobar resection in the high-risk group.Conclusions: Gender, albumin level, carcinoembryonic antigen level and cytokeratin-19-fragment level are valuable markers in predicting recurrence and can guide surgical practice in patients with stage IA LUAD.
Background: The tumor and node metastasis (TNM) staging and pathological grading systems are currently insufficient for accurately predicting recurrence‐free survival (RFS) in patients with pathological stage (p‐stage) I lung adenocarcinoma (LUAD). Therefore, there is an urgent need for a more economical and applicable clinical prediction model to assess the risk of recurrence and guide clinical postoperative care. Methods: This retrospective study included 544 patients with p‐stage I LUAD who were randomly allocated to development (272 patients) and validation (272 patients) cohorts. Cox regression and backward model selection were used to develop the prediction model. The predictive performance of the model was then compared with that of the current TNM staging system and two major pathological grading systems. The primary endpoint was RFS. Results: A total of 79 out of 544 patients with p‐stage I LUAD experienced recurrence after surgery. Four risk factors were incorporated into a weighted risk index—high‐grade patterns ratio, epidermal growth factor receptor mutation status, spread through air spaces status and consolidation tumor ratio—to establish the “CEHS” RFS prediction model. This model demonstrated superior predictive accuracy compared with existing staging and grading systems. High‐risk patients had significantly shorter RFS than low‐risk patients did. An online algorithm based on the CEHS model was also developed. Conclusion: We established and validated a novel model that integrates radiological, molecular and pathological features to predict RFS in patients with p‐stage I LUAD. This new model exhibited excellent discriminatory power for classifying early‐stage LUAD patients at different risks of recurrence.